Recent Updates — AAPG

Ascentage Pharma announced that China’s National Medical Products Administration granted a Breakthrough Therapy Designation for its Bcl-2 inhibitor, lisaftoclax, in combination with acalabrutinib. The designation applies to the first-line treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not previously received systemic therapy. This regulatory milestone accelerates development and review pathways for the drug candidate in China. Ascentage Pharma is a global, commercial-stage integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies to address unmet medical needs in cancer.

Ascentage Pharma Group International filed its 2026 Interim Report covering the six months ended June 30, 2026. Revenue increased 29.3% to RMB302.2 million (US$44.5 million), driven by a 32.6% rise in product sales to RMB282.4 million. Total operating expenses grew 36.1% to RMB1,042.7 million due to increased research and development spending of RMB697.5 million and selling expenses of RMB226.4 million for Lisaftoclax marketing. The net loss widened to RMB817.0 million (US$120.4 million) from RMB590.8 million in the prior year period, while cash balances decreased 23.3% to RMB1,895.6 million. The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer on August 3, 2026. Ascentage Pharma is a global biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.

Ascentage Pharma Group International reported unaudited financial results for the six months ended June 30, 2026. Revenue increased 29% year-over-year to US$44.5 million (RMB302.2 million), driven by a 32.6% rise in product sales to US$41.6 million. The company posted a net loss of US$120.4 million, compared to US$82.5 million in the prior year period. Cash and bank balances decreased 23.3% to US$279.4 million due to increased research and development expenses associated with global clinical trials. Ascentage Pharma appointed Dr. Faiçal Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer. The company also removed the “B” marker from its Hong Kong Stock Exchange short name, indicating it met higher market capitalization and revenue thresholds. Ascentage Pharma is a global biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.